GRI Bio (GRI) to Release Quarterly Earnings on Thursday

GRI Bio (NASDAQ:GRI) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect GRI Bio to post earnings of ($6.80) per share for the quarter.

GRI Bio Trading Up 2.8 %

Shares of NASDAQ:GRI opened at $6.70 on Thursday. The firm has a market cap of $3.52 million, a PE ratio of -0.58 and a beta of -2.10. The company has a fifty day simple moving average of $9.08 and a 200 day simple moving average of $10.63. GRI Bio has a 12-month low of $5.12 and a 12-month high of $186.97.

Analyst Ratings Changes

Several brokerages have recently issued reports on GRI. Ascendiant Capital Markets boosted their price target on shares of GRI Bio from $204.00 to $221.00 and gave the company a “buy” rating in a report on Thursday, December 5th. HC Wainwright began coverage on GRI Bio in a research note on Monday, December 9th. They issued a “buy” rating and a $170.00 price target for the company.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.